Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

G protein antagonists.

M Freissmuth¹, M Waldhoer, E Bofill-Cardona

¹Institute of Pharmacology, University of Vienna, Austria.

Trends in Pharmacological Sciences

|June 15, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Allosteric modulators of solute carrier function: a theoretical framework.

Frontiers in physiology·2023

Same author

Late-onset palsy of the recurrent laryngeal nerve after thyroid surgery.

The British journal of surgery·2014

Same author

Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

British journal of pharmacology·2014

Same author

The conservative view: is it necessary to implant a stent into the dopamine transporter?

British journal of pharmacology·2014

Same author

Risk factors for postoperative bleeding after thyroid surgery.

The British journal of surgery·2012

Same author

The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55.

British journal of pharmacology·2011

Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026

Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026

Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026

Same journal

Biosensors for translatable GPCR bias.

Trends in pharmacological sciences·2026

Same journal

ECM stiffness and epigenetics in organ fibrosis.

Trends in pharmacological sciences·2026

Same journal

Which HTT transcript to lower?

Trends in pharmacological sciences·2026

See all related articles

Heterotrimeric G proteins are key drug targets. Inhibiting their specific binding sites offers novel therapeutic strategies beyond traditional receptor modulation for various diseases.

Area of Science:

Biochemistry
Pharmacology
Cellular Signaling

Background:

Heterotrimeric G proteins link cell surface receptors to intracellular effectors like ion channels and enzymes.
Current drug therapies primarily target receptors or second messenger pathways (e.g., phosphodiesterase inhibitors).
G protein activation involves conformational changes exposing binding sites for receptors, nucleotides, and effectors.

Purpose of the Study:

To summarize structural and mechanistic data on G protein antagonists.
To present arguments for targeting G proteins directly as a therapeutic strategy.

Main Methods:

Review of existing literature on G protein structure, function, and inhibition.
Analysis of binding sites on G protein subunits (alpha and betagamma).

Related Experiment Videos

Evaluation of the potential for small molecule inhibitors to block G protein activity.

Main Results:

G protein subunits undergo sequential activation/deactivation cycles, exposing critical interaction domains.
Inhibitors can block these exposed binding sites, offering a distinct mechanism from receptor antagonists.
Structural insights reveal druggable pockets within the G protein complex.

Conclusions:

G proteins represent a viable and distinct drug target class.
Targeting G proteins directly offers potential for novel therapeutic interventions.
Further research into G protein antagonists could lead to new pharmacotherapies.